2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Ta5f,Necrobiosis lipoidica (NL) is a rare, chronic granulomatous skin disease for which no US Food and Drug Administration (FDA)-approved treatments exist. PCS499, an oral deuterated pentoxifylline analog, may offer therapeutic benefit. To evaluate the safety and exploratory efficacy of PCS499 in adults with biopsy-confirmed NL. A phase 2, open-label nonrandomized clinical trial (from January 2019-February 2020) with a 6-month treatment period with an optional 6-month extension was conducted at the University of Pennsylvania and University of Pittsburgh dermatology research centers. Adults aged 18 to 80 years with biopsy-confirmed NL were eligible. Inclusion required a reference lesion of 10 cm2 or larger and Investigator Global Assessment (IGA) of NL activity score of 2 or greater (scale 0-5). Key exclusions were recent corticosteroid, immunosuppressant, biologic, phototherapy, or pentoxifylline-class use; significant comorbidities; and pregnancy or lactation. Data were analyzed in May 2025. PCS499, 900 mg, orally twice daily for 6 months, with optional 6-month extension. Safety was assessed through adverse event (AE) monitoring, laboratory testing, and electrocardiograms. Exploratory efficacy end points included changes from baseline in IGA, Physician Global Assessments and Patient Global Assessments (PGA, PtGA), NL Color and Ulcer Scale (NLCUS), Dermatology Life Quality Index (DLQI), and Skindex-29 scores. Twelve participants were enrolled (median [range] age, 41 [19-66] years; all female individuals; 10 [83%] with diabetes; mean [SD] disease duration, 12.7 [9.3] years), and 10 completed treatment. The most common AE was mild gastrointestinal symptoms (33%). No serious AEs or clinically significant laboratory abnormalities occurred. Participants with ulcerated NL (n = 2 [17%]) achieved complete ulcer closure by day 85 and day 351 without recurrence. Six participants (50%) achieved clear or almost clear IGA status (median [range] time, 111 [54-166] days). Significant improvements were observed in IGA activity (median [IQR] change, -1.5 [-2.0 to 0.0]; P = .03), PGA (median [IQR] change, -1.3 [-2.8 to -0.9]; P = .04), NLCUS inflammation/color (median [IQR] change, -1.0 [-1.8 to 0.0]; P = .02), and induration (median [IQR] change, -1.0 [-2.0 to 0.0]; P = .04), and Skindex-29 function scores (median [IQR] change, -14.6 [-27.1 to 3.1]; P = .05). This nonrandomized clinical trial found that PCS499 was safe and well tolerated, with evidence of clinical and quality-of-life improvement, particularly in ulcerated NL; however, larger trials are warranted. ClinicalTrials.gov Identifier: NCT03698864.31:T123c, Importance Necrobiosis lipoidica (NL) is a rare, chronic granulomatous skin disease for which no US Food and Drug Administration (FDA)–approved treatments exist. PCS499, an oral deuterated pentoxifylline analog, may offer therapeutic benefit. Objective To evaluate the safety and exploratory efficacy of PCS499 in adults with biopsy-confirmed NL. Design, Setting, and Participants A phase 2, open-label nonrandomized clinical trial (from January 2019-February 2020) with a 6-month treatment period with an optional 6-month extension was conducted at the University of Pennsylvania and University of Pittsburgh dermatology research centers. Adults aged 18 to 80 years with biopsy-confirmed NL were eligible. Inclusion required a reference lesion of 10 cm 2 or larger and Investigator Global Assessment (IGA) of NL activity score of 2 or greater (scale 0-5). Key exclusions were recent corticosteroid, immunosuppressant, biologic, phototherapy, or pentoxifylline-class use; significant comorbidities; and pregnancy or lactation. Data were analyzed in May 2025. Intervention PCS499, 900 mg, orally twice daily for 6 months, with optional 6-month extension. Main Outcomes and Measures Safety was assessed through adverse event (AE) monitoring, laboratory testing, and electrocardiograms. Exploratory efficacy end points included changes from baseline in IGA, Physician Global Assessments and Patient Global Assessments (PGA, PtGA), NL Color and Ulcer Scale (NLCUS), Dermatology Life Quality Index (DLQI), and Skindex-29 scores. Results Twelve participants were enrolled (median [range] age, 41 [19-66] years; all female individuals; 10 [83%] with diabetes; mean [SD] disease duration, 12.7 [9.3] years), and 10 completed treatment. The most common AE was mild gastrointestinal symptoms (33%). No serious AEs or clinically significant laboratory abnormalities occurred. Participants with ulcerated NL (n = 2 [17%]) achieved complete ulcer closure by day 85 and day 351 without recurrence. Six participants (50%) achieved clear or almost clear IGA status (median [range] time, 111 [54-166] days). Significant improvements were observed in IGA activity (median [IQR] change, −1.5 [−2.0 to 0.0]; P = .03), PGA (median [IQR] change, −1.3 [−2.8 to −0.9]; P = .04), NLCUS inflammation/color (median [IQR] change, −1.0 [−1.8 to 0.0]; P = .02), and induration (median [IQR] change, −1.0 [−2.0 to 0.0]; P = .04), and Skindex-29 function scores (median [IQR] change, −14.6 [−27.1 to 3.1]; P = .05). Conclusions and Relevance This nonrandomized clinical trial found that PCS499 was safe and well tolerated, with evidence of clinical and quality-of-life improvement, particularly in ulcerated NL; however, larger trials are warranted. Trial Registration ClinicalTrials.gov Identifier: NCT03698864 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Phosphodiesterase Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Phosphodiesterase Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Phosphodiesterase%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Phosphodiesterase Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Phosphodiesterase%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"Phosphodiesterase Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Phosphodiesterase Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1038/s41581-026-01117-6","pmid":"42697978","title":"Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes","journal_title":"Nature Reviews Nephrology","journal_issn":"1759-5061","published_at":"2026-09-04T00:00:00.000Z","url":"https://doi.org/10.1038/s41581-026-01117-6","source_score":9,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-08T06:32:03.090Z","updated_at":"2026-09-08T06:32:03.090Z","tags":[{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"brand","value":"Baricitinib","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"condition","value":"Atherosclerosis","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"condition","value":"Cardiovascular Disease","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"condition","value":"Chronic Kidney Disease","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"generic","value":"bardoxolone","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"generic","value":"pentoxifylline","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"generic","value":"ruboxistaurin","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"generic","value":"selonsertib","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"ASK1 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"IL-1β Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"IL-6 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"Non-Steroidal Mineralocorticoid Antagonist","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"Nrf2 Activator","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"Phosphodiesterase Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"PKCβ Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"RAAS Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"modality","value":"SGLT2 Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"warning","value":"Brand tag for baricitinib (Olumiant) was not explicitly named in the abstract; the generic name was used instead.","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"warning","value":"Level of evidence set to 7 (narrative expert review); no systematic search methodology or GRADE assessment is described in the abstract.","value_numeric":null},{"paper_doi":"10.1038/s41581-026-01117-6","tag_type":"warning","value":"Several investigational agents discussed (selonsertib, ruboxistaurin) have had failed or halted clinical programs; the review may not fully reflect the most current trial statuses as of publication.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates inflammation as a therapeutic target in chronic kidney disease (CKD), examining how systemic and local inflammatory pathways drive kidney damage, atherosclerosis, and cardiac dysfunction, and assessing both investigational and proven anti-inflammatory treatments.","key_result":"Multiple inflammatory pathways (ASK1, JAK1/2, PKCβ, Nrf2, PDE, IL-1β, IL-6) have been targeted in CKD trials with mixed results; established therapies (RAAS inhibitors, SGLT2i, GLP-1 RAs, ns-MRAs) also carry anti-inflammatory properties that may partly explain their cardio-renal benefits.","limitations":"As a narrative review, it does not provide pooled effect sizes or head-to-head comparisons; several investigational agents (e.g., selonsertib, ruboxistaurin) have had limited or failed trial programs, and causality between inflammation reduction and hard outcomes remains incompletely established.","practice_takeaway":"Clinicians should recognize that hsCRP elevation signals heightened cardiovascular and CKD progression risk, and that selecting proven therapies with anti-inflammatory properties (SGLT2 inhibitors, GLP-1 receptor agonists, ns-MRAs, RAAS inhibitors) may provide additive benefit beyond blood pressure or glucose control alone."}},{"doi":"10.1016/j.ajog.2026.05.022","pmid":"42248442","title":"Combinational Tocolysis: Evaluating Lower-Dose Combinations of Nifedipine, Indomethacin and Aminophylline for Tocolytic Synergism in Pregnant Human Myometrium","journal_title":"American Journal of Obstetrics and Gynecology","journal_issn":"0002-9378","published_at":"2026-06-04T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajog.2026.05.022","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:08.979Z","updated_at":"2026-06-10T14:24:08.979Z","tags":[{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"condition","value":"Preterm Labor","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"generic","value":"aminophylline","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"generic","value":"indomethacin","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"generic","value":"nifedipine","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"modality","value":"Calcium Channel Blocker","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"modality","value":"COX Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"modality","value":"Phosphodiesterase Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"modality","value":"Tocolytic","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"sample_size","value":"n=24","value_numeric":24},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"study_design","value":"Ex Vivo Experimental Study","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"warning","value":"Level of evidence set to 6 (laboratory/ex vivo study) given the preclinical nature; no standard LOE hierarchy cleanly fits this design.","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"warning","value":"Sample size is very small (n=6 per group); total N tagged as 24 (4 groups × 6), but groups may share some tissue donors — not clarified in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.ajog.2026.05.022","tag_type":"warning","value":"Study design is ex vivo only; findings cannot be directly applied to clinical practice without in vivo or clinical trial validation.","value_numeric":null}],"summaries":{"what_studied":"This ex vivo study tested whether dual and triple combinations of nifedipine, indomethacin, and aminophylline produce synergistic tocolysis in pregnant human myometrial tissue strips undergoing spontaneous rhythmic contractions, using the Bliss Independence Model to compare expected vs. observed inhibition at IC25 and IC50 concentrations.","key_result":"Nifedipine + indomethacin and nifedipine + aminophylline both showed synergism (IC50 observed 0.86 and 0.92 vs. expected 0.72, p=0.0003 and p=0.0002, respectively; n=6 each); the triple combination also synergized (IC25 observed 0.73 vs. expected 0.51, p=0.0004), achieving near-complete contractility inhibition at IC25 doses. Indomethacin + aminophylline was only additive (p=0.25).","limitations":"- All findings are from ex vivo myometrial strips (n=6 per group), with no in vivo, animal, or clinical data to confirm translation.\n- Very small sample size limits statistical robustness.\n- Optimal dosing ratios and pharmacokinetics in clinical settings remain untested.","practice_takeaway":"These results are preclinical only and not yet ready for clinical use, but they suggest that nifedipine-based dual or triple tocolytic combinations may allow lower individual drug doses while preserving or enhancing efficacy. Clinicians should watch for forthcoming trials evaluating these combinations for short-term tocolysis (≤48 hours) before corticosteroid administration or maternal transfer."}},{"doi":"10.1161/circresaha.125.327866","pmid":"42063407","title":"Chronic Erythrocyte NO Production Accelerates Atherosclerosis by Increasing SMC De Novo Lipogenesis","journal_title":"Circulation Research","journal_issn":"0009-7330","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.1161/circresaha.125.327866","source_score":20,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-22T13:24:15.453Z","updated_at":"2026-06-22T13:24:15.453Z","tags":[{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"condition","value":"Atherosclerosis","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"condition","value":"Dyslipidemia","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"generic","value":"arginase-1","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"generic","value":"CD36 inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"generic","value":"PDE2A inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"modality","value":"Acetyl-CoA Carboxylase Inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"modality","value":"Fatty Acid Synthase Inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"modality","value":"Phosphodiesterase Inhibitor","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"study_design","value":"Animal Experimental Study","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"warning","value":"Sample sizes for in vivo atherosclerosis experiments are not provided in the abstract or results section — effect size confidence is difficult to assess.","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"warning","value":"Study is entirely preclinical (mouse model); no human subjects or clinical outcomes data are reported.","value_numeric":null},{"paper_doi":"10.1161/circresaha.125.327866","tag_type":"warning","value":"The study design tag 'Animal Experimental Study' is used as no standard canonical label for mechanistic mouse studies fits typical clinical study design categories.","value_numeric":null}],"summaries":{"what_studied":"This mouse study examined how chronically elevated erythrocyte-derived NO — achieved by genetic deletion of arginase-1 in red blood cells (RBC.ARG1-KO) — affects smooth muscle cell (SMC) lipid metabolism and atherosclerosis progression in hypercholesterolemic apolipoprotein E-deficient mice.","key_result":"RBC.ARG1-KO SMCs showed increased lipid droplet formation driven by simultaneous upregulation of lipid uptake (CD36), catabolism (CPT1A), and de novo lipogenesis (ACACA, FASN) genes; the mechanism involved overactivated sGC-cGMP signaling, loss of PDE2A, and downstream AMPK inhibition unlocking acetyl-CoA carboxylase. Hypercholesterolemic RBC.ARG1-KO mice had greater aortic Oil Red O-positive atherosclerosis burden and elevated polyunsaturated long-chain cholesterol esters confirmed by mass spectrometry lipidomics.","limitations":"Findings are based entirely on mouse models (genetic KO and ApoE-deficient); direct human translational relevance is not established. Sample sizes for in vivo atherosclerosis quantification are not reported in the abstract. The model uses constitutive ARG1 deletion in RBCs, which may not fully reflect pathophysiological conditions of erythrocyte NO excess in humans.","practice_takeaway":"PDE2A emerges as a molecular switch linking chronic NO signaling to SMC lipid accumulation — a potential therapeutic target for atherosclerosis, though all data are preclinical and no human studies have been conducted."}},{"doi":"10.1001/jamadermatol.2026.0863","pmid":"42054009","title":"Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-04-29T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13130064/","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-06","doi":"10.1001/jamadermatol.2026.0863","days":"14","issn":"2168-6068","rank":"8","field":"Clinical Medicine","score":"11","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2026.0863","title":"Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"Twelve participants were enrolled (median [range] age, 41 [19-66] years; all female individuals; 10 [83%] with diabetes; mean [SD] disease duration, 12.7 [9.3] years), and 10 completed treatment. The most common AE was mild gastrointestinal symptoms (33%). No serious AEs or clinically significant laboratory abnormalities occurred. Participants with ulcerated NL (n = 2 [17%]) achieved complete ulcer closure by day 85 and day 351 without recurrence. Six participants (50%) achieved clear or almost clear IGA status (median [range] time, 111 [54-166] days). Significant improvements were observed in IGA activity (median [IQR] change, -1.5 [-2.0 to 0.0]; P = .03), PGA (median [IQR] change, -1.3 [-2.8 to -0.9]; P = .04), NLCUS inflammation/color (median [IQR] change, -1.0 [-1.8 to 0.0]; P = .02), and induration (median [IQR] change, -1.0 [-2.0 to 0.0]; P = .04), and Skindex-29 function scores (median [IQR] change, -14.6 [-27.1 to 3.1]; P = .05).","abstract":"$30","keywords":[],"pubmed_id":"42054009","conclusions":"","publication_date":"2026-04-29T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2026.0863","URL":"https://doi.org/10.1001/jamadermatol.2026.0863","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2848176/jamadermatology_rubenstein_2026_br_260004_1777042050.63363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica"],"author":[{"given":"Ayelet I.","family":"Rubenstein","sequence":"first","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"Maya","family":"Das","sequence":"additional","affiliation":[{"name":"Processa Pharmaceuticals, Hanover, Maryland"}]},{"given":"Mary","family":"Nyberg","sequence":"additional","affiliation":[{"name":"Processa Pharmaceuticals, Hanover, Maryland"}]},{"given":"Sian","family":"Bigora","sequence":"additional","affiliation":[{"name":"Processa Pharmaceuticals, Hanover, Maryland"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[{"name":"Processa Pharmaceuticals, Hanover, Maryland"}]},{"given":"Ellen","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia"}]},{"given":"Laura","family":"Ferris","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Now with Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia"}]}],"issued":{"date-parts":[[2026,4,29]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-29T15:30:24Z","timestamp":1777476624000,"date-parts":[[2026,4,29]]},"indexed":{"date-time":"2026-05-02T23:51:51Z","timestamp":1777765911467,"date-parts":[[2026,5,2]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2848176"}},"subtitle":["A Nonrandomized Clinical Trial"],"deposited":{"date-time":"2026-04-29T15:30:27Z","timestamp":1777476627000,"date-parts":[[2026,4,29]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,4,29]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaad.2013.05.034","key":"dbr260004r1","year":"2013","issue":"5","author":"Reid","volume":"69","first-page":"783","unstructured":null,"article-title":"Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1684/ejd.2015.2636","key":"dbr260004r2","year":"2015","issue":"6","author":"Erfurt-Berge","volume":"25","first-page":"595","unstructured":null,"article-title":"Updated results of 100 patients on clinical features and therapeutic options in necrobiosis lipoidica in a retrospective multicentre study.","journal-title":"Eur J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2018.5635","key":"dbr260004r3","year":"2019","issue":"4","author":"Hashemi","volume":"155","first-page":"455","unstructured":null,"article-title":"Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.16856","key":"dbr260004r5","year":"2023","issue":"12","author":"Nihal","volume":"62","first-page":"1529","unstructured":null,"article-title":"Treatment options for necrobiosis lipoidica: a systematic review.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2023.11.027","key":"dbr260004r6","year":"2024","issue":"9","author":"Hwang","volume":"144","first-page":"1994","unstructured":null,"article-title":"Topical ruxolitinib in the treatment of necrobiosis lipoidica: a prospective, open-label study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/BF03348204","key":"dbr260004r7","year":"2003","issue":"10","author":"Basaria","volume":"26","first-page":"1037","unstructured":null,"article-title":"Necrobiosis lipoidica diabeticorum: response to pentoxiphylline.","journal-title":"J Endocrinol Invest","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejphar.2006.02.017","key":"dbr260004r8","year":"2006","issue":"1-3","author":"Fantin","volume":"535","first-page":"301","unstructured":null,"article-title":"Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties.","journal-title":"Eur J Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1177/1060028018797110","key":"dbr260004r10","year":"2019","issue":"2","author":"Russak","volume":"53","first-page":"211","unstructured":null,"article-title":"Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.","journal-title":"Ann Pharmacother","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.08.048","key":"dbr260004r12","year":"2023","issue":"6","author":"Hashemi","volume":"89","first-page":"1305","unstructured":null,"article-title":"Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomes.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.jid.5701142","key":"dbr260004r13","year":"2007","issue":"12","author":"Both","volume":"127","first-page":"2726","unstructured":null,"article-title":"Critical review of generic and dermatology-specific health-related quality of life instruments.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20985","key":"dbr260004r14","year":"2022","issue":"3","author":null,"volume":"186","first-page":"e111","unstructured":null,"article-title":"A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.15137","key":"dbr260004r15","year":"2023","issue":"10","author":"Schiefer-Niederkorn","volume":"21","first-page":"1120","unstructured":null,"article-title":"Necrobiosis lipoidica in childhood: a review of literature with emphasis on therapy.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":null,"key":"dbr260004r4","year":"2008","issue":null,"author":"Kalus","volume":null,"first-page":"1467","unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dbr260004r9","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Pentoxifylline? FDA. U.S. National Library of Medicine. Accessed January 21, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"dbr260004r11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Library of Medicine. A Phase 2 Study of PCS499 for the Treatment of Ulcerated and Nonulcerated Necrobiosis Lipoidica. Updated November 2, 2018. Accessed July 3, 2025. https://clinicaltrials.gov/study/NCT04172779","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":15,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,29]]},"references-count":15,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2026.0863","is_oa":true,"title":"Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica","updated":"2026-05-04T08:56:22+00:00","published_date":"2026-04-29","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13130064/","pmh_id":"oai:pubmedcentral.nih.gov:13130064","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13130064/"}}},"created_at":"2026-05-07T17:34:04.436Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"condition","value":"Necrobiosis Lipoidica","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"generic","value":"PCS499","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"modality","value":"Phosphodiesterase Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"sample_size","value":"n=12","value_numeric":12},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"study_design","value":"Phase 2 Open-Label Nonrandomized Clinical Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"warning","value":"All 12 enrolled participants were female, severely limiting generalizability to male patients with NL.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"warning","value":"Full text was not accessible via the publisher page; summary is based solely on the abstract and results sections provided.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"warning","value":"PCS499 does not yet have an established RxNorm canonical name or brand name; tagged under its investigational identifier.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0863","tag_type":"warning","value":"The ulcerated NL subgroup consisted of only 2 participants — results for this group should be interpreted with extreme caution.","value_numeric":null}],"summaries":{"what_studied":"A phase 2 open-label nonrandomized trial evaluated PCS499 (oral deuterated pentoxifylline analog, 900 mg twice daily) over 6 months (with optional 6-month extension) in 12 adults aged 18–80 with biopsy-confirmed necrobiosis lipoidica (NL) and IGA ≥2, conducted at two U.S. academic dermatology centers (Jan 2019–Feb 2020).","key_result":"10 of 12 participants completed treatment; 50% (n=6) achieved clear or almost clear IGA status (median 111 days). Both participants with ulcerated NL achieved complete ulcer closure (by day 85 and day 351) without recurrence. Significant improvements were seen in IGA activity (median change −1.5, P=.03), PGA (median change −1.3, P=.04), NLCUS inflammation/color (P=.02), induration (P=.04), and Skindex-29 function scores (P=.05). The most common adverse event was mild GI symptoms (33%); no serious adverse events occurred.","limitations":"Very small sample (n=12), all female, no control arm — results may not generalize to males or broader populations. Open-label design without randomization limits causal inference. Single-disease subgroup findings (ulcerated NL, n=2) are difficult to interpret at this scale.","practice_takeaway":"For patients with refractory NL — especially ulcerated cases — PCS499 showed a favorable safety profile and meaningful clinical response in this small pilot trial. Clinicians should be aware this is early-phase evidence; larger controlled trials are needed before routine use."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Phosphodiesterase Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Phosphodiesterase Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Phosphodiesterase Inhibitor"}}}]]

Papers